Biotechnology News and Research

RSS

Oncolytics Biotech submits Orphan Drug Designation for high grade gliomas in pediatric patients

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) today announced that it has submitted an application for Orphan Drug Designation to the U.S. Food and Drug Administration ("FDA") for REOLYSIN® for the treatment of high grade gliomas (HGG) in pediatric patients.

9 Feb 2015

Artificial mini-organism: An alternative to animal testing

No one wishes to dispense with the blessings of modern medicine, which took away the dread of many diseases. The flipside of the coin: To ensure that effective and safe medications are available, experiments on animals in research laboratories are indispensable.

9 Feb 2015

New RT-DC technology enables faster and continuous mechanical screening of cells

Cells, like any other material, have mechanical properties that can serve for their characterization. For example, cancer cells are characteristically more deformable than healthy cells.

9 Feb 2015

Investigators develop microbiome map of New York City subway system

The microbes that call the New York City subway system home are mostly harmless, but include samples of disease-causing bacteria that are resistant to drugs -- and even DNA fragments associated with anthrax and Bubonic plague -- according to a citywide microbiome map published today by Weill Cornell Medical College investigators.

9 Feb 2015

Two researchers receive Pioneer Award from Human Gene Therapy

Recognized for their pioneering work in the development of gene transfer technology using retroviral vectors to deliver therapeutic genes into cells, Richard C. Mulligan, PhD, Director of the Harvard Gene Therapy Initiative, Harvard Institutes of Medicine, Boston, MA, and A. Dusty Miller, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, received the Pioneer Award from Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

9 Feb 2015

Personalized prevention, treatments of cancer now accessible through Stanford University's new genetics course

Instrumental research that aims to enhance how we predict, diagnose and design personalized prevention and treatments of cancer is now accessible through Stanford University's latest professional education course, Understanding Cancer at the Genetic Level.

9 Feb 2015

Overview of chlamydia trachomatis infections

RnRMarketResearch.com adds "Chlamydia Trachomatis Infections - Pipeline Review, H1 2015" research to its store.

8 Feb 2015

Helsinn begins elsiglutide Phase IIB trial for prevention of chemotherapy-induced diarrhea

Helsinn Healthcare S.A. and Zealand Pharma A/S jointly announce that Helsinn has started a Phase IIB clinical dose-finding trial of elsiglutide for the prevention of chemotherapy-induced diarrhea (CID). The first patients out of a planned total of 600 patients with colorectal cancer treated with chemotherapy have been dosed in the trial.

8 Feb 2015

New study provides better understanding of how stem cells give rise to tumors

Researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) have discovered a precise stem cell signaling process that can lead to intestinal tumors if disrupted. The findings add to our understanding of how stem cells give rise to tumors and identify specific stem cell molecules that may be targeted to prevent the onset, progression, and recurrence of intestinal cancers.

6 Feb 2015

Asterias Biotherapeutics prices underwritten public offering of common stock at $3.90 per share

Asterias Biotherapeutics, Inc., a leading biotechnology company in the emerging field of regenerative medicine, today announced today that it has priced an underwritten public offering of its common stock at a price of $3.90 per share.

6 Feb 2015

RXi closes exclusive global license agreement with Hapten Pharmaceuticals for Samcyprone

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering and developing innovative therapies addressing high-unmet medical needs, today announced the closing of its previously disclosed exclusive global license agreement for the therapeutic use of Samcyprone with Hapten Pharmaceuticals, LLC.

5 Feb 2015

Scientists awarded Agri-Tech Catalyst funding to develop new varieties of pearl millet to tackle diabetes

Scientists at Aberystwyth University's IBERS (Institute of Biological, Environmental and Rural Sciences) have been awarded £250,000 of Agri-Tech Catalyst funding for an 18 month project to develop new varieties of pearl millet.

5 Feb 2015

Images reveal new insights into how kidney develops into a complex organ

Striking images reveal new insights into how the kidney develops from a group of cells into a complex organ.

5 Feb 2015

BioClinica reports 2014 as record year for its eClinical technologies business unit

BioClinica®, Inc., a specialty clinical trials services and technology provider, today announced that 2014 was a record year for its eClinical technologies business unit, with sales soaring 51 percent above the previous year.

From Clario 4 Feb 2015

Can-Fite BioPharma completes patient enrollment in CF101 Phase II/III psoriasis trial

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that all patients enrolled in its Phase II/III psoriasis trial for the Company's drug candidate CF101 have completed the study's 32 week treatment protocol.

4 Feb 2015

Research: New molecule safeguards heart from toxic breast cancer drugs, kills cancerous tumour

A new molecule has been found that protects the heart from toxic breast cancer drugs and also kills the cancerous tumour. The research from Italy addresses the burgeoning problem of heart disease in cancer survivors and is announced by the European Society of Cardiology today on World Cancer Day.

4 Feb 2015

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen today announced a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 501 compared with Humira® (adalimumab) in patients with moderate-to-severe rheumatoid arthritis met its primary and key secondary endpoints.

4 Feb 2015

BioMed Realty Trust expands footprint in Seattle's core innovation district of South Lake Union

BioMed Realty Trust, Inc. today announced that it is under contract to acquire the 307 Westlake Avenue North building in the heart of the burgeoning South Lake Union life science market of Seattle, Washington for approximately $90 million.

4 Feb 2015

Congressman Fattah meets with Amarantus regarding research efforts for degenerative brain diseases

Congressman Chaka Fattah (D-PA), architect of the Fattah Neuroscience Initiative, met last week with Amarantus, a biotechnology company on their recent efforts to develop treatment and diagnostics for degenerative brain diseases, including Alzheimer's.

4 Feb 2015

Serum Institute of India to use Genticel's Vaxiclase platform to develop pertussis vaccines

Genticel, a French biotechnology company and leading developer of therapeutic vaccines, today announces that it has licensed its Vaxiclase technology to Serum Institute of India Ltd., for use as a component in acellular multivalent combination vaccines including pertussis antigens.

3 Feb 2015

Biotechnology News and Research

Oncolytics Biotech submits Orphan Drug Designation for high grade gliomas in pediatric patients

Artificial mini-organism: An alternative to animal testing

New RT-DC technology enables faster and continuous mechanical screening of cells

Investigators develop microbiome map of New York City subway system

Two researchers receive Pioneer Award from Human Gene Therapy

Personalized prevention, treatments of cancer now accessible through Stanford University's new genetics course

Overview of chlamydia trachomatis infections

Helsinn begins elsiglutide Phase IIB trial for prevention of chemotherapy-induced diarrhea

New study provides better understanding of how stem cells give rise to tumors

Asterias Biotherapeutics prices underwritten public offering of common stock at $3.90 per share

RXi closes exclusive global license agreement with Hapten Pharmaceuticals for Samcyprone

Scientists awarded Agri-Tech Catalyst funding to develop new varieties of pearl millet to tackle diabetes

Images reveal new insights into how kidney develops into a complex organ

BioClinica reports 2014 as record year for its eClinical technologies business unit

Can-Fite BioPharma completes patient enrollment in CF101 Phase II/III psoriasis trial

Research: New molecule safeguards heart from toxic breast cancer drugs, kills cancerous tumour

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

BioMed Realty Trust expands footprint in Seattle's core innovation district of South Lake Union

Congressman Fattah meets with Amarantus regarding research efforts for degenerative brain diseases

Serum Institute of India to use Genticel's Vaxiclase platform to develop pertussis vaccines

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News